Nutriband Inc. (NASDAQ:NTRB) saw its stock rise 8% on Friday following news that the U.S. Food and Drug Administration (FDA) has approved a Type C Meeting for its lead product, AVERSA FENTANYL — an abuse-deterrent fentanyl transdermal system.

Scheduled as a virtual face-to-face session on September 18, 2025, the meeting will offer the company feedback on the Chemistry, Manufacturing, and Controls (CMC) aspects of the product from submission through to approval and market launch. This discussion will take place with the FDA’s Division of Anesthesiology, Addiction Medicine, and Pain Medicine.

Nutriband is advancing the product in collaboration with Kindeva, integrating Nutriband’s AVERSA abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch. The technology embeds aversive agents into transdermal patches to combat abuse, diversion, misuse, and accidental drug exposure.

If given the green light, AVERSA FENTANYL would become the first opioid patch globally to feature abuse-deterrent properties aimed at minimizing misuse and accidental exposure risks associated with fentanyl patches. The company projects potential peak U.S. annual sales between $80 million and $200 million.

Protected by patents in 46 countries — including the U.S., Europe, Japan, and China — the AVERSA abuse deterrent technology is initially targeting the U.S. market but Nutriband plans to expand availability to key global healthcare markets.

Nutriband stock price

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.